/MDGL
MDGL Stock - Madrigal Pharmaceuticals, Inc.
Healthcare|BiotechnologyNASDAQ
$591.02+8.56%
+$46.61 (+8.56%) • Dec 19
81
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
High Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.100
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).74
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+11.8%upside
Target: $660.76
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for MDGL
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$585.11 – $596.93
TARGET (TP)$660.78
STOP LOSS$543.74
RISK/REWARD1:1.5
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta-1.05
52W High$605.00
52W Low$265.00
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $180.13M | N/A | N/A | N/A | N/A |
| Gross Profit | $173.90M | $-527,000 | N/A | N/A | $-471,000 |
| Gross Margin | 96.5% | N/A | N/A | N/A | N/A |
| Operating Income | $-497,875,000 | $-380,496,000 | $-293,571,000 | $-242,482,000 | $-206,320,000 |
| Net Income | $-465,892,000 | $-373,630,000 | $-295,350,000 | $-241,846,000 | $-202,244,000 |
| Net Margin | -258.6% | N/A | N/A | N/A | N/A |
| EPS | $-21.90 | $-19.99 | $-17.23 | $-14.63 | $-13.09 |
Company Overview
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis. The company also develops MGL-3745, a backup compound to resmetirom. It has research, development, and commercialization agreement with Hoffmann-La Roche. Madrigal Pharmaceuticals, Inc. is headquartered in West Conshohocken, Pennsylvania.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
8
57%
Hold / Neutral
4
29%
Sell / Underperform
2
14%
Analyst Consensus🟡 Mixed
8 Bullish6 Neutral/Bearish
Price Targets
$323
Average Target
↓ 45.4% Downside
Now
$75
Low
$323
Average
$580
High
Based on 14 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| November 5th 2025 | Cantor Fitzgerald | Upgrade | Overweight | - |
| November 3rd 2025 | BofA Securities | Upgrade | Neutral | $445 |
| October 15th 2025 | Truist | Initiation | Buy | $580 |
| September 4th 2025 | H.C. Wainwright | Resumed | Buy | $500 |
| February 28th 2025 | B. Riley Securities | Upgrade | Buy | $422← $236 |
| February 27th 2025 | H.C. Wainwright | Reiterated | Buy | $405← $400 |
| June 28th 2024 | Cantor Fitzgerald | Initiation | Neutral | - |
| June 11th 2024 | Wolfe Research | Initiation | Outperform | $382 |
| April 22nd 2024 | BofA Securities | Initiation | Underperform | $150 |
| March 15th 2024 | B. Riley Securities | Upgrade | Neutral | $270← $155 |
| March 6th 2024 | Citigroup | Initiation | Buy | $382 |
| February 26th 2024 | B. Riley Securities | Downgrade | Sell | $155 |
| December 20th 2022 | Oppenheimer | Reiterated | Outperform | $250← $170 |
| December 19th 2022 | Raymond James | Upgrade | Market Perform | - |
| December 19th 2022 | Piper Sandler | Reiterated | Overweight | $280← $203 |
Earnings History & Surprises
MDGLBeat Rate
50%
Last 18 quarters
Avg Surprise
-4.6%
EPS vs Estimate
Beats / Misses
9/9
Last 12 quarters
Latest EPS
$-5.08
Q4 2025
EPS Surprise History
Q1 24
-6.8%
$-5.68vs$-5.32
Q2 24
-21.8%
$-7.38vs$-6.06
Q3 24
+6.0%
$-7.10vs$-7.55
Q4 24
+29.1%
$-4.92vs$-6.94
Q1 25
+37.3%
$-2.71vs$-4.32
Q2 25
+8.3%
$-3.32vs$-3.62
Q3 25
+45.4%
$-1.90vs$-3.48
Q4 25
-149.4%
$-5.08vs$-2.04
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | Apr 29, 2026 | — | — | — | — |
Q1 2026 | Feb 25, 2026 | $0.24 | — | — | — |
Q4 2025 | Nov 4, 2025 | $-2.04 | $-5.08 | -149.4% | ✗ MISS |
Q3 2025 | Aug 5, 2025 | $-3.48 | $-1.90 | +45.4% | ✓ BEAT |
Q2 2025 | May 1, 2025 | $-3.62 | $-3.32 | +8.3% | ✓ BEAT |
Q1 2025 | Feb 26, 2025 | $-4.32 | $-2.71 | +37.3% | ✓ BEAT |
Q4 2024 | Oct 31, 2024 | $-6.94 | $-4.92 | +29.1% | ✓ BEAT |
Q3 2024 | Aug 7, 2024 | $-7.55 | $-7.10 | +6.0% | ✓ BEAT |
Q2 2024 | May 7, 2024 | $-6.06 | $-7.38 | -21.8% | ✗ MISS |
Q1 2024 | Feb 28, 2024 | $-5.32 | $-5.68 | -6.8% | ✗ MISS |
Q4 2023 | Nov 6, 2023 | $-4.78 | $-5.34 | -11.7% | ✗ MISS |
Q3 2023 | Aug 8, 2023 | $-4.47 | $-4.69 | -4.9% | ✗ MISS |
Q2 2023 | May 9, 2023 | $-4.98 | $-4.23 | +15.1% | ✓ BEAT |
Q1 2023 | Feb 23, 2023 | $-4.41 | $-4.98 | -12.9% | ✗ MISS |
Q4 2022 | Nov 3, 2022 | $-4.05 | $-4.75 | -17.3% | ✗ MISS |
Q3 2022 | Aug 4, 2022 | $-3.76 | $-4.14 | -10.1% | ✗ MISS |
Q2 2022 | May 9, 2022 | $-3.75 | $-3.36 | +10.4% | ✓ BEAT |
Q1 2022 | Feb 24, 2022 | $-3.92 | $-3.78 | +3.6% | ✓ BEAT |
Q4 2021 | Nov 4, 2021 | $-3.89 | $-3.79 | +2.6% | ✓ BEAT |
Q3 2021 | Aug 5, 2021 | $-3.55 | $-3.72 | -4.8% | ✗ MISS |
Latest News
Madrigal Pharmaceuticals shares are trading higher after Piper Sandler raised the price target from $540 to $900.
📈 PositiveBenzinga•Dec 19, 2025, 06:46 PM
Piper Sandler Maintains Overweight on Madrigal Pharmaceuticals, Raises Price Target to $900
📈 PositiveBenzinga•Dec 19, 2025, 12:48 PM
B. Riley Securities Maintains Buy on Madrigal Pharmaceuticals, Raises Price Target to $670
📈 PositiveBenzinga•Dec 11, 2025, 05:01 PM
HC Wainwright & Co. Maintains Buy on Madrigal Pharmaceuticals, Raises Price Target to $620
📈 PositiveBenzinga•Nov 21, 2025, 04:18 PM
Oppenheimer Maintains Outperform on Madrigal Pharmaceuticals, Raises Price Target to $650
📈 PositiveBenzinga•Nov 20, 2025, 11:08 AM
Truist Securities Maintains Buy on Madrigal Pharmaceuticals, Raises Price Target to $640
📈 PositiveBenzinga•Nov 19, 2025, 05:50 PM•Also:
Canaccord Genuity Maintains Buy on Madrigal Pharmaceuticals, Raises Price Target to $587
📈 PositiveBenzinga•Nov 13, 2025, 09:00 PM•Also:
HC Wainwright & Co. Maintains Buy on Madrigal Pharmaceuticals, Raises Price Target to $568
📈 PositiveBenzinga•Nov 11, 2025, 04:21 PM
Madrigal Pharma Presents 2-Yr Data From Open-Label Compensated MASH Cirrhosis Arm Of Phase 3 MAESTRO-NAFLD-1 Trial, At AASLD 2025
➖ NeutralBenzinga•Nov 10, 2025, 01:02 PM
Madrigal upgraded at Cantor on Rezdiffra launch
📈 PositiveSeeking Alpha•Nov 5, 2025, 07:26 PM
Cantor Fitzgerald Upgrades Madrigal Pharmaceuticals to Overweight
📈 PositiveBenzinga•Nov 5, 2025, 01:19 PM
Citizens Maintains Market Outperform on Madrigal Pharmaceuticals, Raises Price Target to $527
📈 PositiveBenzinga•Nov 5, 2025, 01:03 PM
Madrigal Pharmaceuticals shares are trading higher after the company reported better-than-expected Q3 sales results.
📈 PositiveBenzinga•Nov 4, 2025, 03:59 PM
Madrigal Pharmaceuticals Q3 EPS $(5.08) Misses $(2.16) Estimate, Sales $287.268M Beat $245.386M Estimate
📉 NegativeBenzinga•Nov 4, 2025, 12:01 PM
B of A Securities Upgrades Madrigal Pharmaceuticals to Neutral, Raises Price Target to $445
📈 PositiveBenzinga•Nov 3, 2025, 12:06 PM
Madrigal Pharmaceuticals Announces Multiple MASH And Rezdiffra Data Presentations At The AASLD's The Liver Meeting Nov 7–11, 2025
➖ NeutralBenzinga•Oct 28, 2025, 12:13 PM
Piper Sandler Maintains Overweight on Madrigal Pharmaceuticals, Raises Price Target to $540
📈 PositiveBenzinga•Oct 15, 2025, 01:59 PM
Truist Securities Initiates Coverage On Madrigal Pharmaceuticals with Buy Rating, Announces Price Target of $580
📈 PositiveBenzinga•Oct 15, 2025, 11:35 AM
Oppenheimer Maintains Outperform on Madrigal Pharmaceuticals, Raises Price Target to $590
📈 PositiveBenzinga•Oct 10, 2025, 05:51 PM
Madrigal Pharmaceuticals shares are trading higher after B. Riley Securities maintained a Buy rating and raised its price target from $460 to $560.
📈 PositiveBenzinga•Sep 29, 2025, 03:57 PM
Frequently Asked Questions about MDGL
What is MDGL's current stock price?
Madrigal Pharmaceuticals, Inc. (MDGL) is currently trading at $591.02 per share. The stock has moved +8.56% today.
What is the analyst price target for MDGL?
The average analyst price target for MDGL is $660.78, based on 1 analyst.
What sector is Madrigal Pharmaceuticals, Inc. in?
Madrigal Pharmaceuticals, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is MDGL's market cap?
Madrigal Pharmaceuticals, Inc. has a market capitalization of $13.11 billion, making it a large-cap company.
Does MDGL pay dividends?
No, Madrigal Pharmaceuticals, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorABVX
Abivax S.A.
$114.94
Mkt Cap: $7.5B
BAX
Baxter International Inc.
$18.96
Mkt Cap: $9.7B
BMRN
BioMarin Pharmaceutical Inc.
$61.15
Mkt Cap: $11.7B
CAI
Caris Life Sciences, Inc.
$27.94
Mkt Cap: $7.9B
EXEL
Exelixis, Inc.
$44.30
Mkt Cap: $11.9B
JAZZ
Jazz Pharmaceuticals plc
$166.99
Mkt Cap: $10.1B
MRNA
Moderna, Inc.
$33.80
Mkt Cap: $13.2B
RNA
Avidity Biosciences, Inc.
$72.34
Mkt Cap: $9.5B
RYTM
Rhythm Pharmaceuticals, Inc.
$112.14
Mkt Cap: $7.5B
TECH
Bio-Techne Corporation
$58.27
Mkt Cap: $9.1B
Explore stocks similar to MDGL for comparison